Skip to content

Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation

WithdrawnNot applicableNCT02546336
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

Brief summary (from the registry)

Hip osteoarthritis (HOA) is a common cause of pain and disability in aging population. Conservative treatment is based on lifestyle modifications, physical therapy, analgesic and anti-inflammatory medications and intra articular injections. This Prospective Pilot Study aims at investigating the efficacy of Ultrasound-Guided Cooled Radiofrequency Hip Denervation as a treatment offered to patients with HOA.

Study details

Official title
Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation: A Prospective Pilot Study
Interventions
  • Device: Ultrasound-Guided Cooled Radiofrequency Hip Denervation
Sponsor
Women's College Hospital
Start date
2019-02-01
Primary completion
2019-02-01
Sex
All
Age range
from 18 Years to 90 Years
Results posted
No results posted in this snapshot
Countries
Canada
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Primary degenerative osteoarthritis of hip joint * Pain pre-intervention qualified as at least moderate with functional limitation moderate/severe. * Radiological confirmation of hip osteoarthritis * Failure of conservative therapy to control symptoms, defined as the persistence of at least moderate with functional limitation moderate/severe pain that has been refractory to prescribed medications, and other modalities, such as physical therapy and intraarticular injections. Intolerable side effects of medications and contraindications to specific methods will be also considered as a failure of the conservative therapy. * Positive articular branches analgesic block, defined as \>50% improvement in pain and function for at least 2 hours Exclusion Criteria: * Non-English speakers * Daily dose of opioids more than 90 MEQ * Body Mass Index (BMI) \> 30 * Uncorrectable coagulopathy * Local and systemic infection * Inability to obtain ultrasound image of ventral acetabulum * Documented prior Anaphylactic Reaction to Contrast Agent * Pregnancy

Canadian sites (1)

FacilityCityProvince
Women's College HospitalTorontoOntario

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02546336